# Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab

> **NCT02559622** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 151 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secukinumab
- **OTHER:** Placebo
- **OTHER:** Placebo
- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT02559622
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559622, "Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02559622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*